Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of RG002C0106 in primary IgA nephropathy
CTR20253001Phase 2Active
- Sponsor
- Shine-On Pharma
- Start
- Jul 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RG002C0106 in IgA nephropathy (IgAN), sponsored by Shine-On Pharma. Started Jul 2025; status: active.
02
Drugs
RG002C0106
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20253001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253001.